News | Heart Failure | May 18, 2018

Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Subgroup analysis of FIX-HF-5 study found CCM therapy with Optimizer device significantly improved exercise tolerance and quality of life for one subset of heart failure patients

Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

May 18, 2018 — In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise tolerance (ET) and quality of life (QoL) for patients with persistent symptomatic heart failure and an ejection fraction between 25 and 45 percent.  Results of the prospective FIX-HF-5C Study were presented at the 2018 Heart Rhythm Society (HRS) Scientific Sessions, May 9-12 in Boston.                     

CCM therapy for patients with persistent symptomatic heart failure (NYHA Class III and IV) consists of nonexcitatory electrical signals delivered to the heart during the absolute refractory period. The objective of the prospective FIX-HF-5C study was to confirm a subgroup analysis of a prior study (FIX- HF-5) showing that CCM significantly improved ET and QoL in the target patient group.

One hundred and sixty patients were randomized to continued medical therapy alone (Control) or to continued medical therapy plus CCM delivered by Impulse Dynamics’ Optimizer system (Treatment) for 24 weeks. All patients had NYHA III or IV symptoms despite guideline recommended therapy, QRS duration <130ms and LVEF 25-45 percent. Peak VO2 (pVO2, primary endpoint), Minnesota Living with Heart Failure Questionnaire (MLWHFQ), NYHA and six-minute hall walk (6MHW) test were measured at baseline, 12 and 24 weeks. Bayesian repeated measures linear modeling was used for the primary endpoint analysis, with 30 percent borrowing from the FIX-HF-5 subgroup. Safety was assessed by the percentage of patients free of device-related adverse events, with a prespecified lower bound of 70 percent.

The difference in pVO2 between Treatment and Control was 0.836 mlO2/kg/min with a 95 percent Bayesian credible interval of (0.123, 1.552 mlO2/kg/min), satisfying the primary endpoint. MLWHFQ (p<0.001), NYHA (p<0.001) and 6MHW (p=0.01) were all better in Treatment vs Control. There were seven device-related events, yielding a lower bound of 80% of patients free of events.

For more information: www.hrssessions.org

Related HRS Content

Heart Rhythm 2018 Late-breaking Studies

Long-Term Data Demonstrate Safety, Efficacy of Optimizer System

Related Content

Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...
Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT) | May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
Overlay Init